Insight Molecular Diagnostics Inc. (IMDX)
NASDAQ: IMDX · Real-Time Price · USD
4.300
-0.130 (-2.93%)
Aug 12, 2026, 2:37 PM EDT - Market open
IMDX Revenue
Insight Molecular Diagnostics had revenue of $239.00K in the quarter ending June 30, 2026, a decrease of -53.86%. This brings the company's revenue in the last twelve months to $1.67M, down -60.77% year-over-year. In the year 2025, Insight Molecular Diagnostics had annual revenue of $4.06M with 115.58% growth.
Revenue (ttm)
$1.67M
Revenue Growth
-60.77%
P/S Ratio
83.14
Revenue / Employee
$28,793
Employees
58
Market Cap
138.85M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 4.06M | 2.17M | 115.58% |
| Dec 31, 2024 | 1.88M | 378.00K | 25.15% |
| Dec 31, 2023 | 1.50M | 545.00K | 56.89% |
| Dec 31, 2022 | 958.00K | -1.24M | -56.41% |
| Dec 31, 2021 | 2.20M | 982.00K | 80.76% |
| Dec 31, 2020 | 1.22M | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Myriad Genetics | 806.60M |
| OPKO Health | 587.90M |
| Castle Biosciences | 357.28M |
| Fulgent Genetics | 323.93M |
| MDxHealth | 110.97M |
| Biodesix | 102.94M |
| Burning Rock Biotech | 74.58M |
| Exagen | 71.12M |
IMDX News
- 22 hours ago - Insight Molecular Diagnostics to Host Virtual KOL Event on August 17, 2026: Moving Toward In-House Heart Transplanted Organ Rejection Testing - GlobeNewsWire
- 1 day ago - Insight Molecular Diagnostics Earnings Call Transcript: Q2 2026 - Transcripts
- 1 day ago - Insight Molecular Diagnostics Shareholder letter: Q2 2026 - Filings
- 1 day ago - Insight Molecular Diagnostics Earnings release: Q2 2026 - Filings
- 1 day ago - Insight Molecular Diagnostics Quarterly report: Q2 2026 - Filings
- 1 day ago - Insight Molecular Diagnostics reports Q2 EPS (31c), consensus (23c) - TheFly
- 8 days ago - iMDx to Release Second Quarter Results on August 10, 2026 and Attend Needham Virtual MedTech & Diagnostics 1x1 Conference - GlobeNewsWire
- 20 days ago - Insight Molecular Diagnostics highlights Lancet study on GraftAssure assay - TheFly